KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.

Bruce Ac Cree, Baldur Magnusson, Nicolas Rouyrre, Robert J Fox, Gavin Giovannoni, Patrick Vermersch, Amit Bar-Or, Ralf Gold, Daniela Piani Meier, Göril Karlsson, Davorka Tomic, Christian Wolf, Frank Dahlke, Ludwig Kappos

Mult Scler 27(10) 1564-1576

PMID33205682
PMCIDPMC8414818
DOI10.1177/1352458520971819
发表日期2020-11-18
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. OBJECTIVE: To distinguish siponimod's direct effects on disability progression from those on relapses in the EXPAND phase 3 trial. METHODS: Three estimands, one based on principal stratum and two on hypothetical scenarios (no relapses, or equal relapses in both treatment arms), were defined to determine the extent to which siponimod's effects on 3- and 6-month confirmed disability progression were independent of on-study relapses. RESULTS: Principal stratum analysis estimated that siponimod reduced the risk of 3- and 6-month confirmed disability progression by 14%-20% and 29%-33%, respectively, compared with placebo in non-relapsing patients. In the hypothetical scenarios, risk reductions independent of relapses were 14%-18% and 23% for 3- and 6-month confirmed disability progression, respectively. CONCLUSION: By controlling the confounding impact of on-study relapses on confirmed disability progression, these statistical approaches provide a methodological framework to assess treatment effects on disability progression in relapsing and non-relapsing patients. The analyses support that siponimod may be useful for treating secondary progressive multiple sclerosis in patients with or without relapses.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。